TARS biotech catalysts & pipeline

TARSUS PHARMACEUTICALS INC · Data as of 2026-10-25

Upcoming catalysts

TP-04 (lotilaner ophthalmic gel) — Topline data

Late 2026

A Phase 2 study of TP-04 (lotilaner ophthalmic gel) for the potential treatment of ocular rosacea (OR), a highly prevalent and underserved eye disease with no FDA-approved therapy, in December 2025, with topline data expected by year-end 2026.

Source filing

lotilaner (TP-05) — Topline data

H1 2027

The Phase 2 KORE trial evaluating TP-04, a lotilaner-based sterile ophthalmic gel formulation for the potential treatment of ocular rosacea, continues to progress, with topline data expected in the first half of 2027.

Source filing

XDEMVY (lotilaner ophthalmic solution) — Regulatory decision

2027

In Europe, on-track for potential approval of a preservative-free formulation in 2027.

Source filing

aqueous chlorine dioxide solution (IRX-101) — Topline data

in 2028

Anticipated to initiate the Phase 3 COMFORT trial of IRX-101, an investigational ocular antiseptic, in the first half of 2027, with topline results expected in 2028.

Source filing

gildeuretinol (ALK-001) — Topline data

H2 2029

Top-line Phase 3 NORTHSTAR data expected in the second half of 2029; Has Received Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations

Source filing

Explore the free biotech catalyst calendar